ClinicalTrials.gg
CompletedNCT02471404Updated Mar 26, 2019Results posted

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

A Phase 4 interventional study of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus and Inadequate Glycaemic Control, sponsored by AstraZeneca. Completed at 173 sites in 5 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
939
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
18th of 180
939 · median 82
Started
2015
with 14 others
Phase 4
77 of 180
7 open now
Registered
62nd of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 15 that started in 2015, is one of 77 in phase 4, and was the 62nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is being carried out to see if dapagliflozin and dapagliflozin plus saxagliptin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glimepiride (sulphonylurea) as an addition to metformin treatment.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Inadequate Glycaemic Control

Keywords

  • Diabetes Mellitus Type 2,
  • metformin,
  • saxagliptin,
  • dapagliflozin,
  • glimepiride,
  • inadequate glycaemic control
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Main Inclusion Criteria:

  1. Is male or female and ≥18 and \<75 years old at time of .
  2. Has a of ≥7.5% and ≤10.5% based on central laboratory results from Visit 1, with individual need for therapy escalation.
  3. Currently treated with a stable maximum tolarated dose (MTD) (≥1500 mg/day) of metformin therapy for at least 8 weeks prior to Enrolment visit.
  4. Has a of ≤45 kg/m2 at Enrolment visit.
  5. Has a C-peptide laboratory value of ≥1.0 ng/mL (0.33 nmol/L; 333.3 pmol/L) based on central laboratory results from Visit 1.

Main, Exclusion Criteria:

  1. Clinically diagnosed with Type I diabetes, known diagnosis of maturity onset diabetes of the young (MODY), or secondary diabetes mellitus or known presence of glutamate decarboxylase 65 (GAD65) antibodies.
  2. Patients who, in the judgment of the Investigator, may be at risk for dehydration or volume depletion that may affect the patient's safety and/or the interpretation of efficacy or safety data.
  3. cardiovascular disease or procedure within 3 months prior to Enrolment or expected to require coronary revascularization procedure during the course of the study.
  4. Concomitant treatment with loop diuretics
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
939 participants (actual)

Study arms

  • Active comparator
    Dapagliflozin+metformin

    Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin

    Drug: Dapagliflozin · Drug: Placebo for saxagliptin · Drug: Placebo for glimepiride

  • Active comparator
    Dapagliflozin+saxagliptin+metformin

    Dapagliflozin + saxagliptin + glimepiride placebo+ metformin

    Drug: Dapagliflozin · Drug: Saxagliptin · Drug: Placebo for glimepiride

  • Active comparator
    Glimepiride+metformin

    Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin

    Drug: Glimepiride · Drug: Placebo for dapagliflozin · Drug: Placebo for saxagliptin

Interventions

  • 10 mg, orally Green, plain, diamond-shaped, film-coated tablet

    Also known as: Forxiga

  • 5 mg, orally Plain, yellow, biconvex, round, film-coated tablet

    Also known as: Onglyza™

  • 1, 2, or 4 mg, orally Opaque gray capsule

    Also known as: Amaryl

  • DrugPlacebo for dapagliflozin

    Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet

  • DrugPlacebo for saxagliptin

    Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet

  • DrugPlacebo for glimepiride

    Does not contain active ingredient, orally. Opaque gray capsule

06

What researchers measure

Primary outcomes

  1. Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52

    Change in HbA1c from baseline (week 0) to week 52.

    Time frame: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

Secondary outcomes

  1. Patients With at Least One Episode of Confirmed Hypoglycaemia

    Percentage of patients reporting at least 1 episode of hypoglycaemia (symptomatic + blood glucose \<=50 mg/dL) during the double-blind treatment period

    Time frame: Up to Week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

  2. Change in Total Body Weight From Baseline at Week 52

    Change in body weight from baseline (week 0) to week 52

    Time frame: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

  3. Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52

    Change in FPG from baseline (week 0) to week 52

    Time frame: Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis

  4. Time to Rescue

    The time to rescue (from first dose date after randomisation to start of rescue medication or discontinuation due to lack of glycaemic control) during the 52 week double blind treatment period

    Time frame: Over the 52 week treatment period

  5. Number of Patients Rescued

    Number (%) of patients rescued.

    Time frame: Over the 52 week treatment period

07

Results

Posted Mar 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneDapagliflozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
Started314312313
Completed281298288
Not completed331425
Withdrew: Adverse event712
Withdrew: Developed study withdrawal criteria412
Withdrew: Failure to meet randomization criteria201
Withdrew: Lost to follow-up113
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject845
Withdrew: Other reasons not specified10712

Outcome measures

PrimaryChange in Haemoglobin A1c (HbA1c) From Baseline to Week 52

Change in HbA1c from baseline (week 0) to week 52.

Time frame:
Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
Reported as:
Least squares mean · HbA1c %
Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52
HbA1c %Dapaglifozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52-0.82 ± 0.049-1.2 ± 0.046-0.99 ± 0.048
Statistical analysis
  • Dapaglifozin 10mg vs Glimepiride 1mg/2mg/4mg · Mixed Models Analysis · Mean difference (final values): 0.16 · 95% CI 0.0294 to 0.2986
  • Saxagliptin 5mg and Dapagliflozin 10mg vs Glimepiride 1mg/2mg/4mg · Mixed Models Analysis · p = 0.001 ((superiority)) · Mean difference (final values): -0.21 · 95% CI -0.3443 to -0.0825
SecondaryPatients With at Least One Episode of Confirmed Hypoglycaemia

Percentage of patients reporting at least 1 episode of hypoglycaemia (symptomatic + blood glucose \<=50 mg/dL) during the double-blind treatment period

Time frame:
Up to Week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
Reported as:
Number · Percentage of participants
Patients With at Least One Episode of Confirmed Hypoglycaemia
Percentage of participantsDapaglifozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
Patients With at Least One Episode of Confirmed Hypoglycaemia00.324.21
Statistical analysis
  • Dapaglifozin 10mg vs Glimepiride 1mg/2mg/4mg · Fisher Exact · p = <0.001 · Risk difference (rd): -4.21 · 95% CI -6.45 to -1.97
  • Saxagliptin 5mg and Dapagliflozin 10mg vs Glimepiride 1mg/2mg/4mg · Fisher Exact · p = <0.001 · Risk difference (rd): -3.89 · 95% CI -6.21 to -1.56
SecondaryChange in Total Body Weight From Baseline at Week 52

Change in body weight from baseline (week 0) to week 52

Time frame:
Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
Reported as:
Least squares mean · Weight (kg)
Change in Total Body Weight From Baseline at Week 52
Weight (kg)Dapaglifozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
Change in Total Body Weight From Baseline at Week 52-3.54 ± 0.231-3.15 ± 0.2191.76 ± 0.224
Statistical analysis
  • Dapaglifozin 10mg vs Glimepiride 1mg/2mg/4mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -5.30 · 95% CI -5.93 to -4.67
  • Saxagliptin 5mg and Dapagliflozin 10mg vs Glimepiride 1mg/2mg/4mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -4.91 · 95% CI -5.52 to -4.29
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Week 52

Change in FPG from baseline (week 0) to week 52

Time frame:
Baseline, week 52. Values recorded after rescue treatment or collected more than 8 days after the last dose date were excluded from the analysis
Reported as:
Least squares mean · FPG (mmol/L)
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52
FPG (mmol/L)Dapaglifozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52-1.62 ± 0.106-2.08 ± 0.100-1.49 ± 0.105
Statistical analysis
  • Dapaglifozin 10mg vs Glimepiride 1mg/2mg/4mg · Mixed Models Analysis · p = 0.374 · Mean difference (final values): -0.13 · 95% CI -0.43 to 0.16
  • Saxagliptin 5mg and Dapagliflozin 10mg vs Glimepiride 1mg/2mg/4mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.59 · 95% CI -0.88 to -0.31
SecondaryTime to Rescue

The time to rescue (from first dose date after randomisation to start of rescue medication or discontinuation due to lack of glycaemic control) during the 52 week double blind treatment period

Time frame:
Over the 52 week treatment period
Reported as:
Median · Weeks
Time to Rescue
WeeksDapaglifozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
Time to RescueNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Dapaglifozin 10mg vs Glimepiride 1mg/2mg/4mg · Regression, Cox · p = 0.777 · Hazard ratio (hr): 0.95 · 95% CI 0.67 to 1.35
  • Saxagliptin 5mg and Dapagliflozin 10mg vs Glimepiride 1mg/2mg/4mg · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.36 · 95% CI 0.23 to 0.57
SecondaryNumber of Patients Rescued

Number (%) of patients rescued.

Time frame:
Over the 52 week treatment period
Reported as:
Number · Percentage of participants
Number of Patients Rescued
Percentage of participantsDapaglifozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
Number of Patients Rescued18.68.321.4

Adverse events

Collected over Adverse Events from signature of informed consent, enrolment, randomisation and throughout the 52 week treatment period and including the follow-up period. Serious Adverse Events from the time of informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin 10mg0/313 (0%)39/313 (12.5%)29/313 (9.3%)
Saxagliptin 5mg and Dapagliflozin 10mg0/312 (0%)22/312 (7.1%)31/312 (9.9%)
Glimepiride 1mg/2mg/4mg0/312 (0%)35/312 (11.2%)37/312 (11.9%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventDapagliflozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
Coronary artery diseaseCardiac disorders1/3133/3122/312
Atrial fibrillationCardiac disorders0/3130/3122/312
CholecystitisHepatobiliary disorders0/3130/3122/312
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders2/3132/3122/312
OsteoarthritisMusculoskeletal and connective tissue disorders1/3131/3122/312
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/3130/3122/312
Cerebrovascular accidentNervous system disorders2/3130/3120/312
Urethral stenosisRenal and urinary disorders2/3130/3120/312
Acute coronary syndromeCardiac disorders0/3130/3121/312
Acute myocardial infarctionCardiac disorders0/3131/3120/312
Most frequent other events
Most frequent other events
EventDapagliflozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mg
NasopharyngitisInfections and infestations29/31331/31237/312

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dapagliflozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mgTotal
Mean57.4 ± 9.3659.2 ± 7.8758.6 ± 8.3858.4 ± 8.58
Age, Customized
Age, Customized(Participants)Dapagliflozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mgTotal
<65232226226684
>=65-<75818685252
>=751023
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mgTotal
Female112122105339
Male202190208600
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapagliflozin 10mgSaxagliptin 5mg and Dapagliflozin 10mgGlimepiride 1mg/2mg/4mgTotal
Asian1304
Black Or African American2226
White311307311929
08

Study locations

173 sites
  • Research Site
    Hodonin, 695 01, Czechia
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Jilove u Prahy, 254 01, Czechia
  • Research Site
    Ostrava - Belsky les, 700 30, Czechia
  • Research Site
    Pardubice, 530 02, Czechia
  • Research Site
    Plzen - Severni Predmesti, 301 00, Czechia
  • Research Site
    Praha - Klanovice, 190 14, Czechia
  • Research Site
    Prelouc, 535 01, Czechia
  • Research Site
    Uherske Hradiste, 686 01, Czechia
  • Research Site
    Zlin, 760 01, Czechia
  • Research Site
    Aschaffenburg, 63739, Germany
  • Research Site
    Bad Homburg, 61348, Germany
  • Research Site
    Bad Mergentheim, 97980, Germany
  • Research Site
    Bad Nauheim, 61231, Germany
  • Research Site
    Bad Neuenahr-Ahrweiler, 53474, Germany
  • Research Site
    Bad Oeynhausen, 32545, Germany
  • Research Site
    Bad Reichenhall, 83435, Germany
  • Research Site
    Berlin, 10115, Germany
  • Research Site
    Berlin, 10409, Germany
  • Research Site
    Berlin, 10629, Germany
  • Research Site
    Berlin, 10787, Germany
  • Research Site
    Berlin, 12627, Germany
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Berlin, 13597, Germany
  • Research Site
    Bochum, 44787, Germany
  • Research Site
    Bochum, 44869, Germany
  • Research Site
    Bonn, 53179, Germany
  • Research Site
    Bünde, 32257, Germany
  • Research Site
    Daaden, 57567, Germany
  • Research Site
    Darmstadt, 64295, Germany
  • Research Site
    Datteln, 45711, Germany
  • Research Site
    Deggingen, 73326, Germany
  • Research Site
    Dippoldiswalde, 01744, Germany
  • Research Site
    Dortmund, 44137, Germany
  • Research Site
    Dresden, 01309, Germany
  • Research Site
    Duisburg, 47179, Germany
  • Research Site
    Erfurt, 99085, Germany
  • Research Site
    Erlangen, 91052, Germany
  • Research Site
    Eschweiler, 52249, Germany
  • Research Site
    Essen, 45136, Germany
  • Research Site
    Essen, 45355, Germany
  • Research Site
    Essen, 45359, Germany
  • Research Site
    Frankfurt am Main, 60594, Germany
  • Research Site
    Frankfurt, 60594, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Freiburg, 79110, Germany
  • Research Site
    Freudenstadt, 72250, Germany
  • Research Site
    Gelnhausen, 63571, Germany
  • Research Site
    Giengen, 89537, Germany
  • Research Site
    Goch, 47574, Germany
  • Research Site
    Grevesmühlen, 23936, Germany
  • Research Site
    Grossheirath, 96269, Germany
  • Research Site
    Göttingen, 37073, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hamburg, 21073, Germany
  • Research Site
    Hamburg, 21109, Germany
  • Research Site
    Hamburg, 22041, Germany
  • Research Site
    Hamburg, 22391, Germany
  • Research Site
    Hamburg, 22607, Germany
  • Research Site
    Hameln, 31785, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Heidelberg, 69115, Germany
  • Research Site
    Herne, 44653, Germany
  • Research Site
    Hildesheim, 31139, Germany
  • Research Site
    Hof, 95030, Germany
  • Research Site
    Hohenmölsen, 06679, Germany
  • Research Site
    Höhenkirchen, 85635, Germany
  • Research Site
    Jerichow, 39319, Germany
  • Research Site
    Kallstadt, 67169, Germany
  • Research Site
    Karlsruhe, 76199, Germany
  • Research Site
    Kassel, 34117, Germany
  • Research Site
    Kiel-Kronshagen, 24119, Germany
  • Research Site
    Köln, 51069, Germany
  • Research Site
    Köthen, 06366, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Leipzig, 04109, Germany
  • Research Site
    Lichtenfels, 96215, Germany
  • Research Site
    Lingen, 49808, Germany
  • Research Site
    Ludwigshafen, 67059, Germany
  • Research Site
    Löhne, 32584, Germany
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    Mannheim, 68161, Germany
  • Research Site
    Mannheim, 68163, Germany
  • Research Site
    Marburg, 35037, Germany
  • Research Site
    Marl, 45770, Germany
  • Research Site
    Meine, 38527, Germany
  • Research Site
    Meißen, 01662, Germany
  • Research Site
    Mühldorf A. Inn, 84453, Germany
  • Research Site
    München, 80339, Germany
  • Research Site
    München, 80809, Germany
  • Research Site
    München, 81477, Germany
  • Research Site
    Münster, 48143, Germany
  • Research Site
    Münster, 48153, Germany
  • Research Site
    Neumünster, 24534, Germany
  • Research Site
    Neuwied Am Rhein, 56564, Germany
  • Research Site
    Oldenburg, 23758, Germany
  • Research Site
    Papenburg, 26871, Germany
  • Research Site
    Pirna, 01796, Germany
  • Research Site
    Rehburg Loccum, 31547, Germany

Showing the first 100 of 173 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Muller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E, Garcia-Sanchez R, Kurlyandskaya R, Sjostrom CD, Jacob S, Seufert J, Dronamraju N, Csomos K. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2018 Nov;20(11):2598-2607. doi: 10.1111/dom.13437. Epub 2018 Jul 16. PubMed 29947099 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Mar 2017, 17 months.

Results were first posted in Mar 2019, 2 years after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 17 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2015
First posted
Jun 15, 2015
StartActual
Sep 21, 2015
Primary completionActual
Mar 13, 2017
CompletionActual
Mar 13, 2017
Results first posted
Mar 26, 2019
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02471404
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Sep 21, 2015
Primary completion
Mar 13, 2017
Completion
Mar 13, 2017
Results posted
Mar 26, 2019
Last update
Mar 26, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Saxagliptin · Glimepiride

Start the discussion